SG10201809673RA - Treatment of androgen deprivation therapy associated symptoms - Google Patents

Treatment of androgen deprivation therapy associated symptoms

Info

Publication number: SG10201809673RA
Authority: SG; Singapore
Prior art keywords: treatment; deprivation therapy; associated symptoms; androgen deprivation; therapy associated
Prior art date: 2014-09-11

Application number

SG10201809673RA

Other languages

English (en)

Inventor

Charles Thomas Benson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-11

Filing date

2015-09-08

Publication date

2018-12-28

2015-09-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2018-12-28 Publication of SG10201809673RA publication Critical patent/SG10201809673RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Neurology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

SG10201809673RA 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms SG10201809673RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462049192P	2014-09-11	2014-09-11

Publications (1)

Publication Number	Publication Date
SG10201809673RA true SG10201809673RA (en)	2018-12-28

Family

ID=54151401

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201809673RA SG10201809673RA (en)	2014-09-11	2015-09-08	Treatment of androgen deprivation therapy associated symptoms
SG11201701630VA SG11201701630VA (en)	2014-09-11	2015-09-08	Treatment of androgen deprivation therapy associated symptoms

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201701630VA SG11201701630VA (en)	2014-09-11	2015-09-08	Treatment of androgen deprivation therapy associated symptoms

Country Status (23)

Country	Link
US (4)	US10758515B2 (zh)
EP (2)	EP3375444A1 (zh)
JP (4)	JP6893171B2 (zh)
KR (5)	KR102619415B1 (zh)
CN (4)	CN108440497A (zh)
AP (1)	AP2017009795A0 (zh)
AU (2)	AU2015315431C1 (zh)
BR (2)	BR112017002449B1 (zh)
CA (2)	CA3067289C (zh)
EA (2)	EA034553B1 (zh)
ES (1)	ES2779978T3 (zh)
HK (1)	HK1252811A1 (zh)
IL (3)	IL279209B2 (zh)
JO (2)	JOP20180072A1 (zh)
MA (1)	MA45416A (zh)
MX (2)	MX373322B (zh)
MY (2)	MY198753A (zh)
NZ (1)	NZ728612A (zh)
SG (2)	SG10201809673RA (zh)
TW (1)	TWI616201B (zh)
UA (1)	UA120099C2 (zh)
WO (1)	WO2016040234A1 (zh)
ZA (1)	ZA201802680B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20180072A1 (ar) *	2014-09-11	2019-01-30	Lilly Co Eli	علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en)	2016-11-16	2018-07-05	Transition Therapeutics (Ireland 2) Limited	Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
US20230096602A1 (en)	2020-01-27	2023-03-30	Eirgen Pharma Ltd.	Tetrahydrocyclopenta[b]indole compounds for treatment of renal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1592658E (pt) *	2003-01-13	2013-06-25	Univ Tennessee Res Foundation	Síntese em larga escala de modulador selectivo de receptor de androgénio
US20110237664A1 (en) *	2004-06-07	2011-09-29	Dalton James T	Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) *	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
WO2007138048A1 (en)	2006-05-31	2007-12-06	Glaxo Group Limited	Novel heterocyclic compounds
AU2007275737A1 (en) *	2006-07-19	2008-01-24	Osurf	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en)	2006-10-03	2008-10-28	Fu Zhun Precision Industry (Shen Zhen) Co., Ltd.	Video graphics array (VGA) card assembly
UA98777C2 (en) *	2006-11-20	2012-06-25	Эли Лилли Энд Компани	Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) *	2007-08-31	2009-05-01	Astrazeneca Ab	Heterocyclic amides and methods of use thereof
US8420624B2 (en)	2007-12-04	2013-04-16	Yung Shin Pharm. Ind. Co., Ltd.	Methods for treating or preventing symptoms of hormonal variations
US8354446B2 (en)	2007-12-21	2013-01-15	Ligand Pharmaceuticals Incorporated	Selective androgen receptor modulators (SARMs) and uses thereof
DK2297100T3 (da) *	2008-05-16	2012-12-17	Lilly Co Eli	Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
US8003689B2 (en) *	2008-06-20	2011-08-23	Gtx, Inc.	Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) *	2009-11-13	2011-12-07	Lilly Co Eli	Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) *	2010-04-26	2015-08-05	上海阳帆医药科技有限公司	硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) *	2010-12-27	2012-08-09	Dainippon Sumitomo Pharma Co Ltd	Ｎ−置換−環状アミノ誘導体からなる医薬
SI2915804T1 (sl) *	2012-10-31	2019-06-28	Fujifilm Toyama Chemical Co., Ltd.	Novi derivati aminov ali njihove soli kot inhibitorji TNF ALFA
RU2695664C1 (ru) *	2013-12-09	2019-07-25	Юсб Байофарма Спрл	Производные имидазопиридина в качестве модуляторов активности tnf
JOP20180072A1 (ar) *	2014-09-11	2019-01-30	Lilly Co Eli	علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

2014
- 2014-09-11 JO JOP/2018/0072A patent/JOP20180072A1/ar unknown
2015
- 2015-08-25 JO JOP/2015/0201A patent/JO3609B1/ar active
- 2015-08-25 TW TW104127732A patent/TWI616201B/zh active
- 2015-09-08 EA EA201891008A patent/EA034553B1/ru active IP Right Revival
- 2015-09-08 US US15/327,054 patent/US10758515B2/en active Active
- 2015-09-08 MY MYPI2017700838A patent/MY198753A/en unknown
- 2015-09-08 KR KR1020227032523A patent/KR102619415B1/ko active Active
- 2015-09-08 ES ES15767383T patent/ES2779978T3/es active Active
- 2015-09-08 JP JP2017513539A patent/JP6893171B2/ja active Active
- 2015-09-08 CN CN201810348598.1A patent/CN108440497A/zh active Pending
- 2015-09-08 BR BR112017002449-7A patent/BR112017002449B1/pt active IP Right Grant
- 2015-09-08 BR BR122018007412-4A patent/BR122018007412B1/pt active IP Right Grant
- 2015-09-08 AP AP2017009795A patent/AP2017009795A0/en unknown
- 2015-09-08 KR KR1020217019807A patent/KR20210083370A/ko not_active Ceased
- 2015-09-08 MA MA045416A patent/MA45416A/fr unknown
- 2015-09-08 MY MYPI2018000825A patent/MY195767A/en unknown
- 2015-09-08 SG SG10201809673RA patent/SG10201809673RA/en unknown
- 2015-09-08 CN CN202110830219.4A patent/CN113521068A/zh active Pending
- 2015-09-08 EA EA201790220A patent/EA033606B1/ru not_active IP Right Cessation
- 2015-09-08 MX MX2017003140A patent/MX373322B/es active IP Right Grant
- 2015-09-08 KR KR1020187010670A patent/KR102024493B1/ko active Active
- 2015-09-08 AU AU2015315431A patent/AU2015315431C1/en active Active
- 2015-09-08 KR KR1020177006425A patent/KR20170040338A/ko not_active Ceased
- 2015-09-08 EP EP18169909.1A patent/EP3375444A1/en not_active Withdrawn
- 2015-09-08 CN CN201580048887.4A patent/CN106794178A/zh active Pending
- 2015-09-08 CA CA3067289A patent/CA3067289C/en active Active
- 2015-09-08 CN CN202110871107.3A patent/CN113651797A/zh active Pending
- 2015-09-08 CA CA2956514A patent/CA2956514C/en active Active
- 2015-09-08 IL IL279209A patent/IL279209B2/en unknown
- 2015-09-08 UA UAA201701774A patent/UA120099C2/uk unknown
- 2015-09-08 WO PCT/US2015/048801 patent/WO2016040234A1/en active Application Filing
- 2015-09-08 NZ NZ728612A patent/NZ728612A/en unknown
- 2015-09-08 SG SG11201701630VA patent/SG11201701630VA/en unknown
- 2015-09-08 KR KR1020197003498A patent/KR20190015628A/ko not_active Ceased
- 2015-09-08 EP EP15767383.1A patent/EP3191094B1/en active Active
2017
- 2017-01-25 IL IL250291A patent/IL250291B/en active IP Right Grant
- 2017-03-09 MX MX2021014120A patent/MX2021014120A/es unknown
- 2017-07-20 HK HK18112116.4A patent/HK1252811A1/zh unknown
2018
- 2018-04-11 IL IL258651A patent/IL258651B/en active IP Right Grant
- 2018-04-18 AU AU2018202714A patent/AU2018202714B2/en active Active
- 2018-04-23 ZA ZA2018/02680A patent/ZA201802680B/en unknown
- 2018-12-11 US US16/216,256 patent/US10799478B2/en active Active
2019
- 2019-01-23 JP JP2019009535A patent/JP6938550B2/ja active Active
2020
- 2020-08-26 US US17/003,648 patent/US20200390744A1/en not_active Abandoned
2021
- 2021-09-01 JP JP2021142082A patent/JP7349480B2/ja active Active
2023
- 2023-07-06 JP JP2023111531A patent/JP2023145479A/ja active Pending
- 2023-12-12 US US18/537,308 patent/US20240148694A1/en active Pending

Also Published As

Publication number	Publication date
US10758515B2 (en)	2020-09-01
JP6938550B2 (ja)	2021-09-22
EA201790220A1 (ru)	2017-07-31
AU2018202714A1 (en)	2018-05-17
AU2015315431C1 (en)	2018-08-02
HK1252811A1 (zh)	2019-06-06
KR20220132669A (ko)	2022-09-30
JP7349480B2 (ja)	2023-09-22
MA45416A (fr)	2019-04-24
JP2022000432A (ja)	2022-01-04
CN108440497A (zh)	2018-08-24
JO3609B1 (ar)	2020-08-27
TW201618782A (zh)	2016-06-01
CN106794178A (zh)	2017-05-31
CN113651797A (zh)	2021-11-16
AP2017009795A0 (en)	2017-03-31
JP6893171B2 (ja)	2021-06-23
SG11201701630VA (en)	2017-03-30
EP3191094B1 (en)	2020-02-19
KR20190015628A (ko)	2019-02-13
MX373322B (es)	2025-03-05
MX2021014120A (es)	2022-01-04
CN113521068A (zh)	2021-10-22
JOP20180072A1 (ar)	2019-01-30
EA034553B1 (ru)	2020-02-19
KR20180041268A (ko)	2018-04-23
IL250291B (en)	2020-09-30
IL279209B2 (en)	2023-02-01
EP3191094A1 (en)	2017-07-19
KR102619415B1 (ko)	2024-01-02
US20200390744A1 (en)	2020-12-17
CA3067289A1 (en)	2016-03-17
BR112017002449B1 (pt)	2022-08-09
IL279209A (en)	2021-01-31
US20170172992A1 (en)	2017-06-22
EP3375444A1 (en)	2018-09-19
MY195767A (en)	2023-02-10
US10799478B2 (en)	2020-10-13
ES2779978T3 (es)	2020-08-21
BR112017002449A2 (pt)	2017-12-05
CA2956514C (en)	2023-04-18
KR20210083370A (ko)	2021-07-06
ZA201802680B (en)	2020-08-26
UA120099C2 (uk)	2019-10-10
CA2956514A1 (en)	2016-03-17
EA201891008A3 (ru)	2019-03-29
JP2019089795A (ja)	2019-06-13
NZ728612A (en)	2018-03-23
IL258651B (en)	2021-02-28
AU2018202714B2 (en)	2019-06-20
KR102024493B1 (ko)	2019-09-23
BR122018007412B1 (pt)	2022-08-23
AU2015315431B2 (en)	2018-03-08
IL258651A (en)	2018-06-28
EA033606B1 (ru)	2019-11-08
US20240148694A1 (en)	2024-05-09
IL250291A0 (en)	2017-03-30
MY198753A (en)	2023-09-23
WO2016040234A1 (en)	2016-03-17
CA3067289C (en)	2023-04-04
US20190111039A1 (en)	2019-04-18
KR20170040338A (ko)	2017-04-12
TWI616201B (zh)	2018-03-01
IL279209B (en)	2022-10-01
MX2017003140A (es)	2017-05-23
JP2023145479A (ja)	2023-10-11
JP2017527584A (ja)	2017-09-21
AU2015315431A1 (en)	2017-03-09
EA201891008A2 (ru)	2018-09-28

Publication	Publication Date	Title
MX2017004471A (es)	2017-11-20	Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2018000396A (es)	2018-05-02	Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2018006674A (es)	2018-11-09	Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12017500493A1 (en)	2017-08-07	Combination therapy
SG10201810401RA (en)	2018-12-28	Pharmaceutical combinations for treating cancer
WO2015095811A3 (en)	2015-10-22	Combination therapy with neoantigen vaccine
MY192055A (en)	2022-07-25	Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
PH12016502352A1 (en)	2017-02-13	Pharmaceutical composition
TW201613578A (en)	2016-04-16	Pharmaceutical combinations
MX2015010829A (es)	2015-12-03	Compuestos terapeuticos y sus usos.
MX2018010223A (es)	2018-11-09	Terapia combinada para tratamiento de cancer de ovario.
MX2015010296A (es)	2016-05-05	Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016014699A (es)	2017-05-02	(s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
EA202193276A1 (ru)	2022-03-29	Способы лечения холангиокарциномы
MX2021014120A (es)	2022-01-04	Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12016502236A1 (en)	2017-02-06	(r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014014814A (es)	2015-02-12	Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX374354B (es)	2025-03-06	Método de curación de heridas.
MY205171A (en)	2024-10-04	Methods of treatment of hypertriglyceridemia
MX2019004200A (es)	2019-08-05	Terapia de combinacion.
MX2020001217A (es)	2020-03-24	Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2016002139A (es)	2016-11-15	Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
MX2016003763A (es)	2016-10-28	Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
MX2020006451A (es)	2020-11-06	Tratamiento de la fibrosis con inositol.
MX2016010919A (es)	2016-11-29	4-bencilsulfonil-2-butenonitrilo.